A comparison of 12‐ and 19‐week CHOP protocols using non‐randomized, contemporaneous controls

Vos, Nathaniel; Pellin, MacKenzie; Vail, David M.

doi:10.1111/vco.12465

Cited by 15 publications

(39 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of DLTs were comparable for both the RBCHOP 1 and RBCHOP 2 cohorts and similar to other published iterations of CHOP‐based protocols 11‐14 ; however, the frequency of grade 3 or 4 neutropenia and dose reduction was significantly less common in the RBCHOP 3 cohort. This is not surprising, given that toxicity can be cumulative and the dogs in RBCHOP 3 only received three cytotoxic chemotherapy treatments for which toxicity was assessed prior to being offered alternative protocols.…”

Section: Discussionsupporting

confidence: 83%

“…Response to treatment remains an important prognostic factor for dogs with lymphoma. Multiple CHOP iterations of varying lengths, dose intensities, and drug sequences have been published resulting in similar outcomes 6,7,10‐16 . Despite the impressive initial response rates of dogs with B‐cell lymphoma to CHOP‐based protocols, a subset of dogs fails to respond to therapy and/or experiences shorter than expected survival times 17 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Benjamin

Sørenmo

Krick³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

Despite high initial response rates, a subset of dogs with B‐cell lymphoma responds less robustly to CHOP‐based chemotherapy and experiences shorter survival. One hundred and four dogs with nodal B‐cell lymphoma were treated with a response‐based CHOP (RBCHOP) protocol modified based on response to individual drugs during the first chemotherapy cycle. Dogs achieving complete (CR) or partial response (PR) at week 3, following treatment with vincristine and cyclophosphamide, received RBCHOP 1 (n = 72), a protocol sequentially rotating vincristine, cyclophosphamide, and doxorubicin. Dogs without a detectable response at week 3 that subsequently achieved CR or PR following treatment with doxorubicin received RBCHOP 2 (n = 14), in which four doses of doxorubicin were given consecutively followed by vincristine and cyclophosphamide. Dogs that failed to respond at week 3 and then to doxorubicin at week 5 assessment were offered rescue chemotherapy (RBCHOP 3, n = 18). Median progression free survival (PFS) and overall survival time (OST) were similar between RBCHOP 1 (PFS 210 days, OST 354 days) and RBCHOP 2 (PFS 220 days, OST 456 days), but significantly shorter for RBCHOP 3 (PFS 34 days, OST 80.5 days, P < 0.001). No presenting signalment nor hematologic variable differentiated patient cohort, however, dogs in RBCHOP 2 and RBCHOP 3 were more likely to have a lymphocytosis at diagnosis (P = 0.02 and 0.04, respectively). Protocol modification based on response during the first cycle resulted in similar toxicity profiles and outcomes to previously published variants of CHOP, and prognosis remained poor for dogs failing to respond during the first treatment cycle.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Introductionmentioning

confidence: 99%

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Benjamin

Sørenmo

Krick³

et al. 2021

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…The presence of anaemia has been previously identified as a prognostic indicator for dogs treated with CHOP‐based chemotherapy 49 but not confirmed by others 9,50 . In our study, anaemia (as per low haemoglobin concentration) was significantly associated with LSSR at 365 days ( P = .028).…”

Section: Discussioncontrasting

confidence: 78%

Peripheral blood cell ratios as prognostic factors in canine diffuse large B‐cell lymphoma treated withCHOPprotocol

Henriques

Felisberto

Constantino‐Casas

et al. 2020

Vet Comparative Oncology

View full text Add to dashboard Cite

Diffuse large B‐cell lymphoma (DLBCL) is the most common haematopoietic tumour in dogs and recognized as clinical model for its human counterpart. Recently, neutrophil‐to‐lymphocyte (NLR) and lymphocyte‐to‐monocyte (LMR) ratios have been shown to predict time‐to‐progression (TTP) and lymphoma‐specific survival (LSS) in dogs with DLBCL treated with CHOP‐based chemotherapy. We retrospectively evaluated in 59 dogs diagnosed with DLBCL the prognostic value of haematological parameters and derived ratios: NLR, LMR, platelet‐to‐lymphocyte (PLR) and platelet‐to‐neutrophil (PNR) ratios for TTP, LSS and associated secondary end‐points (time‐to‐progression‐rate [TTPR] and lymphoma‐specific survival‐rate [LSSR]) as rates at 180 and 365 days. PNR is an independent prognostic marker (p ≤ .001) for TTPR/180 and 365 days, dogs with a PNR above 0.032 were more likely to progress before 180 days (sensitivity 46.5%, specificity 87.5%, p = .004). On univariate analysis, NLR showed a prognostic significance for LSSR/180 (p = .006) and LSSR/365 (p = .009). A baseline NLR value below 7.45 was positively associated with survival at 180 days (sensitivity 52%, specificity 85.3%, p = .025). The presence of substage b, was associated with early progression and decreased survival at 180 days (p = .031). Anaemia significantly reduced LSSR at 365 days (p = .028). This is the first study evaluating PLR and PNR in canine DLBCL and demonstrates that PNR could be a predictor of early lymphoma progression. Since peripheral blood cell composition can be affected by several non‐oncological causes, the development of larger multicenter studies with homogeneous inclusion criteria could help to better determine the true predictive values of blood cell ratios in dogs' DLBCL treated with CHOP chemotherapy.

show abstract

“…There were no correlations between endocannabinoid levels and lymphoma immunophenotype. In our population, the dogs with T cell lymphoma had a shorter PFI (79.5 days) compared to the dogs with B cell lymphoma (237 days) which is consistent with prior reports of shorter PFI in multicentric T cell lymphoma (1,34). The lack of difference in the measured endocannabinoids suggests that they are not a factor responsible for the more aggressive biologic behavior of T cell lymphoma.…”

Section: Discussionsupporting

confidence: 89%

Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients

et al. 2022

View full text Add to dashboard Cite

The endocannabinoid system is increasingly being implicated in the pathogenesis and progression of various human cancers. Specifically, increased levels of 2-arachidonoylglycerol (2-AG) and oleoythanolamide (OEA) have been demonstrated in human diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL) patients, respectively. The objectives of this paper were to compare 2-AG, OEA, N-arachidonoylethanolamine (AEA), and palmitoylethanolamide (PEA) levels between dogs with multicentric lymphoma and healthy control dogs. In addition, evaluate 2-AG, OEA, AEA, and PEA levels as biomarkers for progression free interval (PFI) and overall survival time (OST) in the dogs with lymphoma. The study consisted of 26 dogs with multicentric B cell lymphoma, 14 dogs with multicentric T cell lymphoma, and 12 healthy control dogs. Serum 2-AG, OEA, AEA, and PEA levels were measured using liquid chromatography combined with tandem mass spectrometry (LC—MS/MS) in dogs with lymphoma and in healthy dogs. OEA, AEA, and PEA levels were significantly elevated in dogs with lymphoma compared to healthy controls (p < 0.05). Total AG was significantly higher in healthy control dogs (p = 0.049). There was no significant difference between dogs with B cell and T cell lymphoma for any of the measured endocannabinoids. Elevated PEA was significantly associated with decreased PFI (p = 0.04) in dogs with lymphoma with a hazards ratio of 1.816 [95% Confidence Interval (CI): 1.020–3.232]. Overall, dogs with lymphoma have elevated levels of OEA, AEA, and PEA. PEA levels have the potential to be a prognostic biomarker.

show abstract

A comparison of 12‐ and 19‐week CHOP protocols using non‐randomized, contemporaneous controls

Cited by 15 publications

References 39 publications

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Response‐based modification of CHOP chemotherapy for canine B‐cell lymphoma

Peripheral blood cell ratios as prognostic factors in canine diffuse large B‐cell lymphoma treated withCHOPprotocol

Circulating Endocannabinoids in Canine Multicentric Lymphoma Patients

Contact Info

Product

Resources

About